

Tiziana Rancati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6151866/publications.pdf>

Version: 2024-02-01

181
papers

4,644
citations

87888

38
h-index

110387

64
g-index

185
all docs

185
docs citations

185
times ranked

4867
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 75-82.	0.6	10
2	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. <i>European Urology Open Science</i> , 2022, 35, 59-67.	0.4	13
3	Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort. <i>Advances in Radiation Oncology</i> , 2022, 7, 100890.	1.2	6
4	Proton Radiation Therapy for Nasopharyngeal Cancer Patients: Dosimetric and NTCP Evaluation Supporting Clinical Decision. <i>Cancers</i> , 2022, 14, 1109.	3.7	8
5	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). <i>Lung Cancer</i> , 2022, 166, 228-241.	2.0	5
6	Artificial intelligence applied to medicine: There is an "elephant in the room". <i>Physica Medica</i> , 2022, 98, 8-10.	0.7	4
7	Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study. <i>Tumori</i> , 2022, , 030089162210780.	1.1	3
8	How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study. <i>Supportive Care in Cancer</i> , 2021, 29, 645-651.	2.2	8
9	Radiobiological Studies of Microvascular Damage through In Vitro Models: A Methodological Perspective. <i>Cancers</i> , 2021, 13, 1182.	3.7	6
10	Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables. <i>Cancers</i> , 2021, 13, 2433.	3.7	8
11	Editorial: Modeling for Prediction of Radiation-Induced Toxicity to Improve Therapeutic Ratio in the Modern Radiation Therapy Era. <i>Frontiers in Oncology</i> , 2021, 11, 690649.	2.8	1
12	Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study. <i>Radiotherapy and Oncology</i> , 2021, 158, 74-82.	0.6	5
13	Predictors of Patient-Reported Incontinence at Adjuvant/Salvage Radiotherapy after Prostatectomy: Impact of Time between Surgery and Radiotherapy. <i>Cancers</i> , 2021, 13, 3243.	3.7	2
14	Spatial descriptions of radiotherapy dose: normal tissue complication models and statistical associations. <i>Physics in Medicine and Biology</i> , 2021, 66, 12TR01.	3.0	14
15	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2021, 159, 241-248.	0.6	11
16	Breast cancer patient perspective on opportunities and challenges of a genetic test aimed to predict radio-induced side effects before treatment: Analysis of the Italian branch of the REQUITE project. <i>Radiologia Medica</i> , 2021, 126, 1366-1373.	7.7	17
17	A Multicentre Evaluation of Dosiomics Features Reproducibility, Stability and Sensitivity. <i>Cancers</i> , 2021, 13, 3835.	3.7	21
18	Modelling Radiation-Induced Salivary Dysfunction during IMRT and Chemotherapy for Nasopharyngeal Cancer Patients. <i>Cancers</i> , 2021, 13, 3983.	3.7	1

#	ARTICLE	IF	CITATIONS
19	The scientific publications of AIFM members in 2015â€“2019: A survey of the FutuRuS working group. <i>Physica Medica</i> , 2021, 88, 111-116.	0.7	1
20	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020, 3, 80-91.	5.4	24
21	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. <i>Cancers</i> , 2020, 12, 2958.	3.7	29
22	Methodology and technology for the development of a prognostic MRI-based radiomic model for the outcome of head and neck cancer patients. , 2020, 2020, 1152-1155.		3
23	A global sensitivity analysis approach applied to a multiscale model of microvascular flow. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2020, 23, 1215-1224.	1.6	4
24	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 541281.	2.8	15
25	Predictors of 2-Year Incidence of Patient-Reported Urinary Incontinence After Post-prostatectomy Radiotherapy: Evidence of Dose and Fractionation Effects. <i>Frontiers in Oncology</i> , 2020, 10, 1207.	2.8	7
26	Towards spatial representations of dose distributions to predict risk of normal tissue morbidity after radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 15, 105-107.	2.9	6
27	Local dose analysis to predict acute and late urinary toxicities after prostate cancer radiotherapy: Assessment of cohort and method effects. <i>Radiotherapy and Oncology</i> , 2020, 147, 40-49.	0.6	17
28	In silico model of the early effects of radiation therapy on the microcirculation and the surrounding tissues. <i>Physica Medica</i> , 2020, 73, 125-134.	0.7	4
29	External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost. <i>Frontiers in Oncology</i> , 2020, 10, 910.	2.8	3
30	T2wâ€™MRI signal normalization affects radiomics features reproducibility. <i>Medical Physics</i> , 2020, 47, 1680-1691.	3.0	82
31	Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?. <i>Frontiers in Psychology</i> , 2020, 11, 576459.	2.1	7
32	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 575909.	2.8	1
33	Genome wide association study of acute radiation toxicity and quality of life in breast cancer patients â€“ results from the REQUITE cohort study. <i>European Journal of Cancer</i> , 2020, 138, S12.	2.8	1
34	PD-0545: Validation of a predictive model for salivary dysfunction during chemo-IMRT for head-neck cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, S303-S304.	0.6	0
35	PH-0119: Modulations of gut microbiota following radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, S60-S61.	0.6	0
36	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 575909.	2.8	10

#	ARTICLE	IF	CITATIONS
37	Patterns in ano-rectal dose maps and the risk of late toxicity after prostate IMRT. <i>Acta Oncologica</i> , 2019, 58, 1757-1764.	1.8	15
38	PO-112 Role of microbiota in predicting oral mucositis in head and neck cancer patients treated with IMRT. <i>Radiotherapy and Oncology</i> , 2019, 132, 57.	0.6	1
39	Introducing Information on Saliva Microbiota into Toxicity Modeling: Preliminary Results from a Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S223-S224.	0.8	0
40	OC-0615 Predicting urinary toxicity via 2D and 3D dose map analyses in prostate cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 133, S326.	0.6	0
41	EP-1923 Dimensionality reduction of radiomic features using a clustering coherence-based approach. <i>Radiotherapy and Oncology</i> , 2019, 133, S1046-S1047.	0.6	0
42	EP-1927 Mechanistic modelling of RT damage to microvasculature and of its effect on tumour microenvironment. <i>Radiotherapy and Oncology</i> , 2019, 133, S1048-S1049.	0.6	0
43	Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer. <i>Oral Oncology</i> , 2019, 99, 104453.	1.5	43
44	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , 2019, 76, 693-702.	1.9	18
45	OC-0161 Validation of clinical/dosimetric/genetic risk factor models for late RT-induced rectal bleeding. <i>Radiotherapy and Oncology</i> , 2019, 133, S78.	0.6	0
46	OC-0647 Analysis of biomarkers for late radiotherapy toxicity in the REQUITE project. <i>Radiotherapy and Oncology</i> , 2019, 133, S343.	0.6	4
47	PO-0837 Dose-effect relationship for early late incontinence after IMRT in post-prostatectomy patients. <i>Radiotherapy and Oncology</i> , 2019, 133, S439-S440.	0.6	0
48	PO-0850 Comparison of self-reported acute urinary incontinence in pts treated with adjuvant or salvage IMRT. <i>Radiotherapy and Oncology</i> , 2019, 133, S446-S447.	0.6	0
49	PO-0851 Quality of life after whole pelvis RT for prostate cancer: results from a prospective study. <i>Radiotherapy and Oncology</i> , 2019, 133, S447-S448.	0.6	0
50	PO-0859 Validation of genetic variants associated to late severe toxicity after prostate cancer RT. <i>Radiotherapy and Oncology</i> , 2019, 133, S452-S453.	0.6	0
51	EP-1190 Preliminary evaluation of salivary cytokines in patients treated with IMRT for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S659-S660.	0.6	0
52	EP-1280 Identification of gene profiles associated to increased risk of acute toxicity in breast cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S702.	0.6	0
53	EP-1663 REQUITE multicentre study of patients undergoing radiotherapy for breast, lung or prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S895.	0.6	0
54	EP-2022 Dose-dependent changes in Tw-MRI texture of obturator muscles after prostate cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 133, S1108-S1109.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Requite Prostate Cohort: Validating Clinical/Dosimetric/Genetic Risk Factors for Late Urinary Toxicity. International Journal of Radiation Oncology Biology Physics, 2019, 105, E317-E318.	0.8	0
56	Development and External Validation of a Predictive Model of Urethra Toxicity for Patients Treated with HDR Brachytherapy Boost Including the Effect of Neo-Adjuvant Androgen Deprivation. International Journal of Radiation Oncology Biology Physics, 2019, 105, S169.	0.8	0
57	Approach Combining Dosimetry and Biology to Predict Severe Toxicity of Radiotherapy for Head and Neck Squamous Cell Carcinomas. International Journal of Radiation Oncology Biology Physics, 2019, 105, S221.	0.8	0
58	OC-0616 Introducing information on gut microbiota into toxicity modeling: preliminary results from a trial. Radiotherapy and Oncology, 2019, 133, S326-S327.	0.6	0
59	REQUIRE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology, 2019, 138, 59-67.	0.6	53
60	In Reply to Loganadane et Al. International Journal of Radiation Oncology Biology Physics, 2019, 103, 777-778.	0.8	1
61	Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations. European Urology Oncology, 2019, 2, 277-285.	5.4	7
62	miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKC μ and ZEB1 inhibition. Journal of Experimental and Clinical Cancer Research, 2019, 38, 51.	8.6	64
63	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	5.4	8
64	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	1.9	58
65	Genetic Variants Predict Optimal Timing of Radiotherapy to Reduce Side-effects in Breast Cancer Patients. Clinical Oncology, 2019, 31, 9-16.	1.4	30
66	Predicting Toxicity in External Radiotherapy. , 2019, , 337-363.		0
67	Texture analysis of T1 ω and T2 ω MR images allows a quantitative evaluation of radiation ω induced changes of internal obturator muscles after radiotherapy for prostate cancer. Medical Physics, 2018, 45, 1518-1528.	3.0	7
68	The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International, 2018, 121, 737-744.	2.5	51
69	Clinical Results for an Active Surveillance Cohort with Localized Prostate Cancer Receiving RT after Exiting Active Surveillance. International Journal of Radiation Oncology Biology Physics, 2018, 102, e145-e146.	0.8	0
70	Evaluation of Inflammatory Marker Levels in Patients Treated with Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e132-e133.	0.8	0
71	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. Oral Oncology, 2018, 86, 266-272.	1.5	26
72	Development of a Ready-to-Use Graphical Tool Based on Artificial Neural Network Classification: Application for the Prediction of Late Fecal Incontinence After Prostate Cancer Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1533-1542.	0.8	14

#	ARTICLE	IF	CITATIONS
73	Predicting Late Fecal Incontinence Risk After Radiation Therapy for Prostate Cancer: New Insights From External Independent Validation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 127-136.	0.8	14
74	OC-0154: REQUITE Big Data Resource for Validating Predictive Models and Biomarkers of Radiotherapy Toxicity. <i>Radiotherapy and Oncology</i> , 2018, 127, S78.	0.6	0
75	PV-0320: NTCP models of late severe urinary symptoms after radical IMRT for prostate cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, S169-S170.	0.6	0
76	PV-0321: Influence of urethra contouring on NTCP models predicting urethral strictures in prostate HDRB. <i>Radiotherapy and Oncology</i> , 2018, 127, S170.	0.6	2
77	SP-0483: The REQUITE project: integrating biomarkers and clinical predictors of radiotherapy side effects. <i>Radiotherapy and Oncology</i> , 2018, 127, S248-S249.	0.6	0
78	PV-0627: Hematologic toxicity after whole-pelvis irradiation: results of a longitudinal observational study. <i>Radiotherapy and Oncology</i> , 2018, 127, S332-S333.	0.6	4
79	PO-0826: Factors affecting self-reported, long-term (1-2 yrs) urinary incontinence from post-prostatectomy RT. <i>Radiotherapy and Oncology</i> , 2018, 127, S431-S432.	0.6	0
80	EP-2009: Metamodelling of late rectal bleeding in patients undergoing radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, S1095.	0.6	0
81	Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy. <i>Disease Markers</i> , 2018, 2018, 1-9.	1.3	13
82	Machine Learning and Radiogenomics: Lessons Learned and Future Directions. <i>Frontiers in Oncology</i> , 2018, 8, 228.	2.8	54
83	Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance. <i>Tumori</i> , 2018, 104, 172-178.	1.1	5
84	Active surveillance in prostate cancer patients: Predicting the chance of continuing AS after re-biopsy. <i>European Urology Supplements</i> , 2018, 17, e781-e782.	0.1	0
85	Active surveillance in prostate cancer patients: Modeling upgrading and upsizing at 1 year rebiopsy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 90-90.	1.6	0
86	Metamodeling of late rectal bleeding in patients undergoing radiotherapy for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 61-61.	1.6	0
87	Data driven approaches I: conventional statistical inference methods, including linear and logistic regression. , 2018, , 85-127.		0
88	Abstract A032: miR-205 reconstitution sensitizes prostate cancer cells and xenografts to radiotherapy, through PKC β suppression. , 2018, , .		0
89	miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. <i>Cancer Letters</i> , 2017, 395, 53-62.	7.2	80
90	Semantics in active surveillance for men with localized prostate cancer " results of a modified Delphi consensus procedure. <i>Nature Reviews Urology</i> , 2017, 14, 312-322.	3.8	65

#	ARTICLE	IF	CITATIONS
91	Dose-Effect Quantification of Patient-Reported Urinary Incontinence After Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E225.	0.8	0
92	Prognostic Value of Metabolic Parameters by 18 F-FDG PET/CT in Nasopharyngeal Cancer (NPC) in Non-Endemic Area. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S164-S165.	0.8	0
93	Incidence of Late Severe Urinary Symptoms after Radical IMRT for Prostate Cancer: Effect of Bladder Doses and Hypofractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S167-S168.	0.8	1
94	Weekly Integral Dose and Use of Lipid Lowering Drugs Are Associated With Worsening of Functional Outcomes in Prostate Cancer Patients Treated With IMRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S182.	0.8	0
95	Dose-Response Curve for Textural Features of Obturator Muscles as Extracted from T2w-MRI after Prostate Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E719.	0.8	0
96	Patient-reported urinary incontinence after radiotherapy for prostate cancer: Quantifying the doseâ€ effect. <i>Radiotherapy and Oncology</i> , 2017, 125, 101-106.	0.6	21
97	PO-0729: Normal Tissue Complication Probability for late urinary toxicities after RT for prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, S382-S383.	0.6	0
98	PO-0896: Quantitative MRI-based characterization of obturator muscles after prostate cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, S494-S495.	0.6	0
99	Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel doseâ€ volume effects. <i>Radiotherapy and Oncology</i> , 2017, 124, 296-301.	0.6	26
100	OC-0038: Patterns in ano-rectal dose maps and the risk of late toxicity after prostate radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, S14-S15.	0.6	0
101	PO-0850: Predicting late fecal incontinence risk after RT for prostate cancer:external independent validation. <i>Radiotherapy and Oncology</i> , 2017, 123, S461.	0.6	1
102	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 274-280.	1.9	11
103	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. <i>Frontiers in Oncology</i> , 2017, 7, 83.	2.8	36
104	Understanding Urinary Toxicity after Radiotherapy for Prostate Cancer: First Steps Forward. <i>Tumori</i> , 2017, 103, 395-404.	1.1	20
105	Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?. <i>Tumori</i> , 2017, 103, 464-474.	1.1	20
106	Predicting late fecal incontinence risk after RT for prostate cancer: External independent validation.. <i>Journal of Clinical Oncology</i> , 2017, 35, 116-116.	1.6	0
107	Comment on â€œObjective assessment in digital images of skin erythema caused by radiotherapyâ€•[<i>Med. Phys.</i> 42, 5568-5577 (2015)]. <i>Medical Physics</i> , 2016, 43, 2687-2688.	3.0	4
108	Predicting toxicity in radiotherapy for prostate cancer. <i>Physica Medica</i> , 2016, 32, 521-532.	0.7	75

#	ARTICLE	IF	CITATIONS
109	Bladder spatial-dose descriptors correlate with acute urinary toxicity after radiation therapy for prostate cancer. <i>Physica Medica</i> , 2016, 32, 1681-1689.	0.7	31
110	Modelling late stool frequency and rectal pain after radical radiotherapy in prostate cancer patients: Results from a large pooled population. <i>Physica Medica</i> , 2016, 32, 1690-1697.	0.7	12
111	A Higher Whole-Pelvic Integral Dose Is Associated With Worsening Fatigue and Functional Outcome in Prostate Cancer Patients Treated With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E269-E270.	0.8	0
112	EP-1858: Variation of apparent diffusion coefficient in penile bulb after radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, S875-S876.	0.6	0
113	Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 13-22.	4.4	30
114	“What if” Decisional Regret in Patients who Discontinued Active Surveillance. <i>Tumori</i> , 2016, 102, 562-568.	1.1	6
115	Bladder dose “surface maps and urinary toxicity: Robustness with respect to motion in assessing local dose effects. <i>Physica Medica</i> , 2016, 32, 506-511.	0.7	22
116	Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 297-304.	2.0	10
117	Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 92-98.	0.6	22
118	First application of a pixel-wise analysis on bladder dose “surface maps in prostate cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, 123-128.	0.6	47
119	The REQUITE Project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 85-85.	1.6	0
120	Modeling severe late rectal bleeding: Results on a large pooled population of prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 82-82.	1.6	0
121	Embracing Phenomenological Approaches to Normal Tissue Complication Probability Modeling: A Question of Method. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 468-471.	0.8	34
122	Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: Results of a cohort study. <i>Radiotherapy and Oncology</i> , 2015, 116, 185-191.	0.6	29
123	Editorial Comment to Health-related quality of life after carbon ion radiotherapy for prostate cancer: A 3 year prospective study. <i>International Journal of Urology</i> , 2014, 21, 375-376.	1.0	0
124	Modelling the Impact of Fractionation on Late Urinary Toxicity After Postprostatectomy Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1250-1257.	0.8	27
125	Long term rectal function after high-dose prostatecancer radiotherapy: Results from a prospective cohort study. <i>Radiotherapy and Oncology</i> , 2014, 110, 272-277.	0.6	30
126	Daily Sodium Butyrate Enema for the Prevention of Radiation Proctitis in Prostate Cancer Patients Undergoing Radical Radiation Therapy: Results of a Multicenter Randomized Placebo-Controlled Dose-Finding Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 518-524.	0.8	29

#	ARTICLE	IF	CITATIONS
127	miRNAs in tumor radiation response: bystanders or participants?. Trends in Molecular Medicine, 2014, 20, 529-539.	6.7	40
128	Relationships between bladder doseâ€“volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer. Radiotherapy and Oncology, 2014, 111, 100-105.	0.6	43
129	Modeling acute urinary toxicity after radiotherapy for prostate cancer.. Journal of Clinical Oncology, 2014, 32, 156-156.	1.6	0
130	The REQUITE project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects.. Journal of Clinical Oncology, 2014, 32, 276-276.	1.6	0
131	Reply from Authors re: Laurence Klotz. Active Surveillance, Quality of Life, and Cancer-related Anxiety. Eur Urol 2013;64:37â€“9. European Urology, 2013, 64, 39-40.	1.9	1
132	Reducing rectal injury during external beam radiotherapy for prostate cancer. Nature Reviews Urology, 2013, 10, 345-357.	3.8	13
133	Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance. European Urology, 2013, 64, 30-36.	1.9	81
134	Impact of the radiotherapy technique on the correlation between doseâ€“volume histograms of the bladder wall defined on MRI imaging and doseâ€“volume/surface histograms in prostate cancer patients. Physics in Medicine and Biology, 2013, 58, N115-N123.	3.0	12
135	Late rectal bleeding after 3D-CRT for prostate cancer: development of a neural-network-based predictive model. Physics in Medicine and Biology, 2012, 57, 1399-1412.	3.0	44
136	Is It Time to Tailor the Prediction of Radio-Induced Toxicity in Prostate Cancer Patients? Building the First Set of Nomograms for Late Rectal Syndrome. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1957-1966.	0.8	41
137	Late Fecal Incontinence After High-Dose Radiotherapy for Prostate Cancer: Better Prediction Using Longitudinal Definitions. International Journal of Radiation Oncology Biology Physics, 2012, 83, 38-45.	0.8	38
138	Contouring Variability of the Penile Bulb on CT Images: Quantitative Assessment Using a Generalized Concordance Index. International Journal of Radiation Oncology Biology Physics, 2012, 84, 841-846.	0.8	41
139	Correlation between surrogates of bladder dosimetry and doseâ€“volume histograms of the bladder wall defined on MRI in prostate cancer radiotherapy. Radiotherapy and Oncology, 2012, 105, 180-183.	0.6	18
140	Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: The case of previous abdominal surgery. Results from a prospective trial. Radiotherapy and Oncology, 2012, 103, 252-255.	0.6	39
141	The 6â€“year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU International, 2012, 110, 998-1003.	2.5	47
142	Centralized revision of diagnostic pathologic slides for prostate cancer patients on active surveillance: Is it just time- and resource-consuming?. Journal of Clinical Oncology, 2012, 30, 132-132.	1.6	0
143	Modeling fecal incontinence symptoms 6 years after high-dose radiation for prostate cancer: Clinical and dosimetric predictors.. Journal of Clinical Oncology, 2012, 30, 71-71.	1.6	0
144	Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. Radiotherapy and Oncology, 2011, 100, 124-130.	0.6	65

#	ARTICLE	IF	CITATIONS
145	Long-term biochemical control of prostate cancer after standard or hyper-fractionation: Evidence for different outcomes between low- ² intermediate and high risk patients. <i>Radiotherapy and Oncology</i> , 2011, 101, 454-459.	0.6	13
146	Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning. <i>Radiation Oncology</i> , 2011, 6, 123.	2.7	17
147	Feasibility of safe ultra-high (EQD ₂ >100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotherapy. <i>Acta Oncologica</i> , 2011, 50, 25-34.	1.8	42
148	Radiation Dose-Volume Effects in the Larynx and Pharynx. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, S64-S69.	0.8	189
149	Predictive models of toxicity in external radiotherapy. <i>Cancer</i> , 2009, 115, 3135-3140.	4.1	39
150	Predictive models of toxicity with external radiotherapy for prostate cancer. <i>Cancer</i> , 2009, 115, 3141-3149.	4.1	33
151	To Bleed or Not to Bleed. A Prediction Based on Individual Gene Profiling Combined With Dose-Volume Histogram Shapes in Prostate Cancer Patients Undergoing Three-Dimensional Conformal Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1431-1440.	0.8	55
152	NTCP Modeling of Subacute/Late Laryngeal Edema Scored by Fiberoptic Examination. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 915-923.	0.8	42
153	Dose-volume effects for normal tissues in external radiotherapy: Pelvis. <i>Radiotherapy and Oncology</i> , 2009, 93, 153-167.	0.6	249
154	Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: Results of a large multicenter observational study. <i>Radiotherapy and Oncology</i> , 2009, 93, 197-202.	0.6	71
155	Clinical and Dosimetric Predictors of Late Rectal Syndrome After 3D-CRT for Localized Prostate Cancer: Preliminary Results of a Multicenter Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1130-1137.	0.8	132
156	Development of a Set of Nomograms to Predict Acute Lower Gastrointestinal Toxicity for Prostate Cancer 3D-CRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1065-1073.	0.8	68
157	Early clinical and radiological pulmonary complications following breast cancer radiation therapy: NTCP fit with four different models. <i>Radiotherapy and Oncology</i> , 2007, 82, 308-316.	0.6	53
158	Predictors for Rectal and Intestinal Acute Toxicities During Prostate Cancer High-Dose 3D-CRT: Results of a Prospective Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1401-1410.	0.8	91
159	Performance of a liquid argon time projection chamber exposed to the CERN West Area Neutrino Facility neutrino beam. <i>Physical Review D</i> , 2006, 74, .	4.7	38
160	Event generators for simulating heavy ion interactions to evaluate the radiation risks in spaceflight. , 2005, , .		0
161	Measurement of the $\hat{1}/4$ decay spectrum with the ICARUS liquid Argon TPC. <i>European Physical Journal C</i> , 2004, 33, 233-241.	3.9	50
162	Analysis of the liquid argon purity in the ICARUS T600 TPC. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2004, 516, 68-79.	1.6	55

#	ARTICLE	IF	CITATIONS
163	Study of electron recombination in liquid argon with the ICARUS TPC. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2004, 523, 275-286.	1.6	87
164	Design, construction and tests of the ICARUS T600 detector. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2004, 527, 329-410.	1.6	362
165	Detection of Cherenkov light emission in liquid argon. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2004, 516, 348-363.	1.6	23
166	Breast irradiation with three conformal photon fields for patients with high lung involvement. Acta Oncologica, 2004, 43, 558-566.	1.8	7
167	Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiotherapy and Oncology, 2004, 73, 21-32.	0.6	183
168	Performance of the ICARUS liquid argon prototype. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2003, 498, 292-311.	1.6	21
169	Observation of long ionizing tracks with the ICARUS T600 first half-module. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2003, 508, 287-294.	1.6	25
170	Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiotherapy and Oncology, 2003, 67, 275-283.	0.6	253
171	Study of the Dosimetric Characteristics of Cosmic Radiation at Civil Aviation Altitudes. Radiation Protection Dosimetry, 2002, 102, 305-314.	0.8	0
172	ICARUS: an innovative detector for underground physics. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2001, 461, 324-326.	1.6	17
173	The ICARUS liquid argon time projection chamber. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2001, 471, 272-275.	1.6	8
174	Calculation of the Radiation Environment Caused by Galactic Cosmic Rays for Determining Air Crew Exposure. Radiation Protection Dosimetry, 2001, 93, 101-114.	0.8	60
175	A 3-dimensional calculation of the atmospheric neutrino fluxes. Astroparticle Physics, 2000, 12, 315-333.	4.3	107
176	Scintillation efficiency of nuclear recoil in liquid xenon. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2000, 449, 147-157.	1.6	63
177	Determination of through-going tracks direction by means of $\hat{\gamma}$ -rays in the ICARUS liquid argon time projection chamber. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2000, 449, 42-47.	1.6	6
178	First observation of 140-cm drift ionizing tracks in the ICARUS liquid-argon TPC. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2000, 449, 36-41.	1.6	9
179	The Role of the Quantities used in Radiological Protection for the Assessment of the Exposure to Cosmic Radiation. Radiation Protection Dosimetry, 1999, 83, 199-210.	0.8	15
180	The Extended Range Neutron Rem Counter LINUS: Overview and Latest Developments. Radiation Protection Dosimetry, 1998, 76, 135-148.	0.8	82

#	ARTICLE	IF	CITATIONS
181	Modelling Radiotherapy Side Effects. , 0 , .		12